Cardiology Guidelines, Guidelines

Rosuvastatin, Kidney Risks, and a Clinical Takeaway

Rosuvastatin

New research from Johns Hopkins further confirms that rosuvastatin use may increase the risk of kidney damage, especially at higher doses. 

Researchers gathered data from 152k patients taking rosuvastatin and nearly 800k on atorvastatin over eight years (3.1-year median follow-up) and found that: 

  • Users of rosuvastatin had an 8% higher risk for hematuria (blood in the urine), a 17% higher risk for proteinuria (protein in the urine), and a 15% higher risk for kidney failure requiring replacement therapy.
  • The risk for hematuria and proteinuria in patients with chronic kidney disease (CKD) increased as rosuvastatin dose increased.
  • The two groups avoided myocardial infarction and stroke to similar extents.

Clinical trials and observational studies linked rosuvastatin to signs of kidney damage when the FDA first approved the drug in 2003, which is why the FDA capped the recommended dosage for people with severe CKD at 10mg/day. 

But the Johns Hopkins researchers found that 44% of patients with advanced kidney disease were prescribed a daily dose exceeding the recommended maximum, suggesting that many clinicians are unaware of rosuvastatin’s dosing recommendations. 

The Takeaway

This study reinforces early reports that rosuvastatin may predispose individuals with advanced CKD to kidney toxicity, and reveals that some clinicians prescribe rosuvastatin at excessive doses. As you might expect, the authors suggested it may be wise to reduce the dosage or discontinue rosuvastatin for these patients.  

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Electrophysiology August 21, 2025

Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025

Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]

Cardiology Pharmaceuticals August 18, 2025

Rivaroxaban Monotherapy Could Be Better for CAD + AFib August 18, 2025

New analysis from the AFIRE trial suggests rivaroxaban monotherapy might be emerging as a preferred antithrombotic strategy for patients with AFib and stable coronary artery disease, especially in older age groups. The Post Hoc AFIRE Analysis examined 2,215 Japanese patients with AFib and stable CAD, stratifying them into four age groups (<70, 70-74, 75-79, and […]

Surgeries & Interventions August 14, 2025

TEER Could Save Lives in AFMR Patients August 14, 2025

Shedding light on a new treatment for an understudied condition, data published in EHJ suggests that transcatheter edge-to-edge repair (TEER) delivers significant survival advantages in patients with atrial functional mitral regurgitation (FMR). The new OCEAN-Mitral/REVEAL-AFMR Analysis compared 441 TEER-treated patients against 640 medically managed controls with moderate or severe atrial FMR, stating a solid case […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!